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Abstract. Background: The prognosis of rhabdomyosarcoma
(RMS) in children and adolescents has improved since the
introduction of multi-agent chemotherapy. However, outcome
data of adults with RMS are scarce. This multicenter
retrospective study investigated the effect of age on outcome of
RMS. Patients and Methods: Data were collected from three
Dutch University Medical Centers between 1977-2009. The
effect of age and clinical prognostic factors on relapse-free and
disease-specific survival (DSS) were analyzed. Results: Age as
a continuous variable predicted poor survival in multivariate
analysis. Five-year DSS was highest for non-metastatic
embryonal RMS, followed by non-metastatic alveolar RMS and
was poor in metastatic disease. Higher age correlated with
unfavorable histological subtype (alveolar RMS) and with
metastatic disease at presentation in embryonal RMS. In non-
metastatic embryonal RMS and in all alveolar RMS, higher age
was an adverse prognostic factor of outcome. Conclusion: This
study indicates that age is a negative predictor of survival in
patients with embryonal and alveolar RMS.  
Rhabdomyosarcoma (RMS) is a soft tissue sarcoma (STS) that
occurs predominantly in children; 70% of cases are diagnosed
within their first decade of life (1, 2). There is a second peak
in incidence during adolescence (age 15-19 years), with RMS
accounting for 1.7% of all malignancies in this age group (3).
In adulthood, RMS is extremely rare, given that STS accounts
for fewer than 1% of all malignancies, and that RMS
comprises only 3.3 % of all STS (4). 
The two main histological subtypes of RMS that occur in
both adults and children are embryonal and alveolar RMS.
Alveolar RMS, which occurs mostly in older children and
adolescents, has a worse outcome compared to embryonal
RMS, which is more common in young children. 
The prognosis in children with RMS has dramatically
improved during the past decades because of the introduction of
multi-agent chemotherapy in consecutive multidisciplinary
clinical trials, and treatment in a centralized setting (5-9). The
Intergroup Rhabdomyosarcoma Study Group (IRSG)
publications demonstrated successive increases in five-year
survival rates between 1972 and 1997; from 55% on IRS-I (5)
to 74% on IRS-IV protocols (8). In contrast, data on adults with
RMS are scarce and in general show a worse outcome compared
to the disease in children (10, 11). Additionally, a recent
Surveillance, Epidemiology and End Results (SEER) report of
2,600 patients with RMS, confirms that no improvements in
adults have been made over the past decades (12). 
The reasons underlying the worse outcome in adult
patients with RMS compared to children remain to be
revealed. From larger pediatric studies, several prognostic
factors have been established, such as site of the primary
tumor (8), size below or above 5 cm diameter (12),
histological subtype (14), stage of disease (15) and age at
diagnosis (16, 17). In the scarce data on adult RMS, nearly
identical factors have been described (10-12, 18-22). 
To further substantiate the differences in outcomes
between children and adults with RMS, the present Dutch
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multicenter study was conducted to investigate the role of
age and other putative prognostic factors on outcome in a
large cohort of both children and adult patients with RMS. 
Patients and Methods
Patients. We selected all patients with RMS in PALGA, the Dutch
National Histopathological Database System, treated at either the
Pediatric Oncology Unit of the Department of Pediatrics or the
Department of Medical Oncology at the University Medical Center
Groningen, the Erasmus Medical Center, Rotterdam, or the Radboud
University Nijmegen Medical Centre diagnosed between 1977 and
2009 (N=226). Patients were excluded if medical files were not
available (N=10), or histological diagnoses were other than
embryonal or alveolar RMS (N=47), as pathology reports were
reviewed. 
Data collection. The following data were collected: age at diagnosis,
gender, site and size of the primary tumor, presence of metastases at
diagnosis, metastatic site, lymph node involvement, treatment
modalities (intention-to-treat principle), and follow-up status.
Histological subtype was defined as embryonal or alveolar RMS.
Botryoid RMS (a subtype of embryonal RMS occurring almost
exclusively in infants and toddlers with a superior outcome) was
analyzed separately. 
Staging. Staging at diagnosis started with physical diagnosis.
Evaluation of the location, size and local extent of the tumor was
additionally evaluated with computerized-tomography (CT) and/or
magnetic resonance imaging (MRI). Regional lymph nodes were
considered positive when suspicious at physical examination, and
when confirmed by CT scanning and/or histological or cytological
evaluation. Further staging included chest X-ray and/or CT scan,
bone scintigraphy and bone marrow aspiration. Pre-treatment
staging in children was based on the IRSG classification (23). Adult
patients were staged according to the TNM classification, based on
local tumor extension and/or fixation to surrounding tissues (T),
tumor size <5 cm or ≥5 cm, lymph node involvement (N) and
presence of metastatic disease (M), and were translated into IRSG
classification to facilitate comparison. Favorable locations of the
primary tumor included the orbit, head and neck but not
parameningeal, and paratesticular sites, whereas unfavorable
locations included all other sites, as stated by the IRSG studies.
Post-surgical clinical grouping (CG) staging was based on the extent
of residual tumor after the initial resection, according to the IRSG
clinical grouping system. 
Treatment. Most children were treated according to the Children’s
Oncology Group (COG) or the International Society of Paediatric
Oncology (SIOP) guidelines (24, 25). Local control consisted of
primary surgery or surgery after neoadjuvant chemotherapy and/or
radiotherapy. Adjuvant systemic treatment consisted of combinations
of vincristine, D-actinomycin, and either iphosphamide or
cyclophosphamide. Anthracyclines were added in the case of
advanced disease. 
Treatment of adults consisted of surgery and/or radiotherapy for
local control following the STS protocols. Additionally, chemotherapy,
mainly consisting of anthracyclines in combination with one or more
of vindesine/vincristine, iphosphamide, and etoposide, was
administered to the majority of adult patients. 
Statistical analyses. Follow-up data were collected in a database
and statistical analyses were performed by Statistics 16.0 (SPSS,
Chicago, IL, USA). Frequency distribution of patient
characteristics and prognostic factors for the different histological
subtypes were assessed with the Chi-square test. The relation
between age and prognostic factors was assessed using non-
parametric testing with the Kruskal Wallis, or the Mann Whitney
U-test when appropriate. 
Overall survival (OS) probabilities were assessed using the Kaplan
Meier method and compared with the log-rank test. OS was defined
as the time from onset of disease until death from any cause. A
multivariate Cox proportional hazards analysis, including age and
other prognostic factors was used to analyze whether age was an
independent prognostic factor in disease-specific survival (DSS) and
relapse-free survival (RFS), using a backward conditional model.
Furthermore, we tested the interaction between the effect of age and
histological subtype on DSS and RFS. Treatment modalities were
selectively tested based on clinical relevance. DSS was defined as the
time from disease onset until death due to disease. RFS was defined as
the time from the end of treatment with complete remission (CR) until
local and/or distant recurrence. CR was defined as no evidence of
residual disease at the end of treatment, confirmed by radiography
and/or histopathology. Patients who never experienced an event were
censored at the last contact date with the hospital and/or medical
correspondence. 
Results
Patients. A total of 169 patients were eligible for analysis.
The median age at diagnosis was 8 years (range 0-73 years).
Because all patients younger than 16 years were treated by a
pediatric oncologist in all centers, we separated our patients
into age groups <16 and ≥16 years. Patients’ and tumor
characteristics are summarized in Table I.
A significantly higher rate of alveolar subtypes and tumors
arising at unfavorable sites (mainly involving parameningeal
and extremity sites), more lymph node involvement, a higher
rate of distant metastasis, a lower probability of CR, a higher
rate of relapse, and a trend towards higher IRS stage was
demonstrated in patients ≥16 years, in comparison to patients
<16 years.
Pre-treatment prognostic factors. Age was significantly related
to histological subtype (p<0.001, Table I, Figure 1A and B).
Embryonal RMS occurred mainly in young children (median
age=7 years). Botryoid RMS mostly occurred in infants and
toddlers (median age=4 years). Alveolar RMS (median age=15
years) showed two peaks in incidence: one in young children
and one in adolescence and young adulthood. 
Because of this strong correlation, we compared
prognostic factors for the different histological subtypes
(Table II). Embryonal RMS was characterized by a
significantly higher rate of favorable primary sites, absence
of regional lymph node involvement and metastatic disease,
with a consequently lower IRS stage at diagnosis when
compared to alveolar RMS. 
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Table I. Patients’ characteristics.
Patients’ characteristics Total Age <16 years Age ≥16 years
N % N % N % p-Valuea 
No. 169 100 118 51
Median age (range), years 8 (0-73) 4 (0-15) 21 (16-73)
Gender (male/female) 97/72 57.1/42.9 70/48 58.8/41.2 27/24 52.9/47.1 0.441
Type N (%) 0.001
Embryonal 103 60.9 78 66.1 25 49.0
Botryoid 15 8.9 14 11.9 1 2.0
Alveolar 51 30.2 26 22.0 25 49.0
Site 0.041
Favorable 59 34.9 47 39.8 12 23.5
Orbit 7 4.1 7 5.9 0 - 
Head/neck (non-PM) 13 7.7 9 7.6 4 7.8
Genito-urinary tractb 39 23.1 31 26.3 8 15.7
Unfavorable 110 65.1 71 60.2 39 76.5
Parameningeal 39 23.1 21 17.8 18 35.3
Extremities 22 13.0 13 11.0 9 17.6
Bladder/prostate 15 8.9 13 11.0 2 3.9
Trunk 7 4.1 4 3.4 3 5.9
Retroperitoneal 7 4.1 7 5.9 0 - 
Perineal/peri-anal 5 3.0 2 1.7 3 5.9
Other 15 8.9 11 9.3 4 7.8
Size 0.332
<5 cm 45 26.6 32 27.1 13 25.5
>5 cm 67 39.6 53 44.9 14 27.5
Unknown 57 33.7 33 28.0 24 47.1
Local tumor extension 0.497
T1 27 16.0 19 16.1 8 15.7
T2 62 36.7 39 33.1 23 45.1
Unknown 80 47.3 70 59.3 20 39.2
Lymph node involvementc 0.011
N1 53 31.4 30 25.4 23 45.1
N0 116 68.6 88 74.6 28 54.9
Metastatic disease 0.02
M1 37 21.9 20 16.9 17 33.3
M0 131 77.5 97 82.2 34 66.7
Unknown 1 0.6 1 0.8 0 - 
IRS staged 0.052
I 56 33.1 45 38.1 11 21.6
II 10 5.9 6 5.1 4 7.8
III 54 32.0 38 32.2 16 31.4
IV 37 21.9 20 16.9 17 33.3
Unknown 12 7.1 9 7.6 3 5.9
Complete remission (%)e 135 79.9 99 83.9 36 70.6 0.048
Relapse 58 34.3 30 25.4 28 54.9 <0.001
Local relapse 21 12.4 14 11.9 7 13.7
Distant relapse 30 17.8 10 8.5 20 39.2
Local and distant relapse 7 4.1 6 5.1 1 2
Time-to-relapse (months)f 5.2 (0.1-73.6) 5.4 (0.1-73.6) 4.5 (0.1-54.5)
Survival after relapse 4.3 (0.3-177.5) 4.4 (0.3-52.0) 3.8 (0.7-177.5)
Follow-up timeg 29.0 (0.1-328.4) 41.7 (0.1-328.4) 16.0 (0.2-197.0)
Alive at last follow-up (%) 85 50.3 74 62.7 11 21.6 <0.001
aChi-square test; bnon-prostate, non-bladder; cevaluated by either histological evaluation, by CT scanning or by clinical examination; dIRS: Intergroup
Rhabdomyosarcoma Study Group (IRSG) pre-operative staging; ecomplete remission (CR) was defined as no evidence of residual disease at the
end of treatment, confirmed by radiography and/or histopathology; ftime-to-relapse is defined as the time from the end of treatment with CR until
disease relapse; gfollow-up time is the time between time of diagnosis until death or the last contact to the hospital.
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Figure 1. A: Frequency distribution by age and histological subtype. B: Age distribution by histological subtype. This figure shows the box plots of
the age distribution by histological subtype. Stepwise non-parametric testing was performed. Age differed significantly between patients with alveolar
(median=15 years) and those with embryonal RMS (median=8 years, p<0.001) and botryoid RMS (median=4 years, p<0.001). There was a trend
for a difference in age between embryonal and botryoid RMS (p=0.084).
In the largest group, namely embryonal RMS, higher age
was related to a higher rate of metastatic disease at diagnosis
(p=0.001) and IRS stage (p=0.002). Within the group of
alveolar RMS, higher age was related to IRS stage
(p=0.026), and there was a trend for a relation between
higher age and greater lymph node involvement (p=0.079).
Tumors arising at unfavorable primary sites (p=0.068), such
as parameningeal versus other primary locations (p<0.001),
were also related to higher age.
Treatment. Out of all 169 patients, six patients did not
receive any treatment due to varying reasons (Table VIII).
Out of the remaining patients (N=163), 22 did not complete
treatment. 
Surgery was performed slightly more frequently in patients
<16 years (p=0.051), whereas radiotherapy was more
frequently administered to patients ≥16 years (p=0.003,
Table III). A significantly lower number of patients ≥16 years
underwent chemotherapy when compared to patients <16
years (p=0.003). The reason why not all patients received
chemotherapy could not be retrieved for all cases. Some
patients were in a poor clinical condition, impairing
administration of chemotherapy; others had had a resection
of a small tumor and were apparently deemed to have been
optimally treated in earlier years of this retrospective study.
Most children received multi-agent chemotherapy but no
anthracyclines (63.5%), with the addition of anthracyclines
only to patients with advanced disease (29.6%). Adults mainly
received anthracycline-based multi-agent chemotherapy,
resulting in a more frequent use of anthracyclines in patients
≥16 years, when compared to patients <16 years (p<0.001).
Survival. Five-year OS for the whole cohort was 52.0±4.0%.
Patients ≥16 years had a disadvantage in outcome when
compared to patients <16 years (5-year OS 21.4±6.4% versus
64.8±4.5%, p<0.001, Figure 2A). 
A significant difference in survival was seen for the
different histological subtypes (Figure 2B). Botryoid RMS had
the best 5-year OS (78.3±11.1%), whereas alveolar RMS
demonstrated poor outcome (5-year OS=21.9±6.1%). Patients
with embryonal RMS had an intermediate 5-year OS of
63.7±4.9%. 
For embryonal RMS, a superior survival was seen in patients
<16 years (5-year OS=71.3±5.2%) versus patients ≥16 years (5-
year OS=37.4±11.0%, p=0.001, Figure 2C). For alveolar RMS,
an advantage in survival for patients <16 years, when compared
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Table II. Pre-treatment prognostic factors by histological subtype. 
Histological subtype
Embryonal RMS Alveolar RMS Botryoid RMS
N % N % N % p-Valuea
All patients 103 51 15
Age, years 7 (0-73) 15 (0-54) 4 (1-19)
Site <0.001
Favorable 48 46.6 7 13.7 4 26.7
Unfavorable 55 53.4 44 86.3 11 73.3
Size 0.685
≤5 cm 31 30.1 11 21.6 3 20.0
>5 cm 47 45.6 13 25.5 7 46.7
Lymph node involvement <0.001
N0 81 78.6 27 52.9 11 73.3
N1 22 21.4 24 47.1 4 26.7
Metastastatic disease <0.001
M0 91 88.3 27 52.9 13 86.7
M1 11 10.7 24 47.1 2 13.3
Local tumor extension 0.029
T1 23 22.3 4 7.8 0 -   
T2 26 25.2 18 35.3 8 53.3
IRS stageb <0.001
IRS 1 47 45.6 5 9.8 4 26.7
IRS 2 4 3.9 5 9.8 1 6.7
IRS 3 34 33.0 14 27.5 6 40.0
IRS 4 11 10.7 24 47.1 2 13.3
aChi-square test; bIRS stage: Intergroup Rhabdomyosarcoma Study Group (IRSG) pre-operative staging. This table displays the frequency distribution
of the prognostic factors by histological subtype.
to patients ≥16 years, was also seen (5-year OS=35.8±9.7%
versus 8.5±5.8%, p=0.020, Figure 2D). In Figure 2E, we show
OS in non-metastatic embryonal RMS (5-year OS=69.1±5.0%),
non-metastatic alveolar RMS (5-year OS=34.1±9.5%), and
metastatic embryonal and alveolar RMS (5-year
OS=11.7±5.9%). Furthermore, within the subgroup of non-
metastatic embryonal RMS, there was a significant disadvantage
in survival for patients ≥16 years (5-year OS=40.0±13.0%),
when compared to children <16 years (75.9±5.1%, p=0.002,
Figure 2F). Exclusion of patients who did not receive
chemotherapy resulted in a 5-year OS 49.2±15.4% in patients
≥16 years versus 78.1±5.0% in patients <16 of age (p=0.021). 
Prognostic factors. All RMS patients: In all RMS patients
(Table IV), increasing age [p<0.001, Hazards Ratio
(HR)=1.028], unfavorable primary site (p=0.012, HR=2.51),
ANTICANCER RESEARCH 32: 4485-4498 (2012)
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Table III. Treatment characteristics by age group.
Total Age <16 years Age ≥16 years
Treatment characteristics N % N % N % p-Valuea
All patients 169 118 51
Curative treatment intent 163 100 115 100 48 100
Chemotherapy 0.003
Yes 154 94.5 113 98.3 41 85.4 
No 8 4.9 2 1.7 6 12.5 
Unknown 1 0.6 0 - 1 2.1 
Drug regimenb
VA containing 125 76.7 108 93.9 17 35.4 <0.001
VA 18 11.0 17 14.8 1 2.1 
VAC/VAI 64 39.3 56 48.7 8 16.7 
VAIA/VACA 42 25.8 34 29.6 8 16.7 
Other combinations with VA 1 0.6 1 0.9 0 - 
DIME 5 3.1 0 - 5 10.4 
EVI 8 4.9 0 - 8 16.7 
Other/unknown 16 9.8 5 4.3 11 22.9 
Anthracyclines <0.001
Yes 64 39.3 36 31.3 28 58.3 
No/unknown 90 55.2 77 67.0 13 27.1 
Radiotherapy 0.003
Yes 81 49.7 48 41.7 32 66.7 
No 81 49.7 66 57.4 15 31.3 
Unknown 2 1.2 1 0.9 1 2.1 
Surgery 0.051
Yes 104 63.8 79 68.7 25 52.1 
Primary tumor 90 55.2 71 61.7 19 39.6 
Primary tumor + metastases 12 7.4 8 7.0 4 8.3 
Metastases 2 1.2 0 - 2 4.2 
No 55 33.7 33 28.7 21 43.8 
Unknown 5 3.1 3 2.6 2 4.2 
Result of surgery 0.082
Radical 48 29.4 32 27.8 16 33.3 
Not radical 43 26.4 37 32.2 6 12.5 
Unknown 13 8.0 7 6.1 3 6.3 
Clinical groupc 0.051
I 38 23.3 25 21.7 13 27.1 
II 25 15.3 22 19.1 3 6.3 
III 53 32.5 38 33.0 14 29.2 
IV 31 19.0 17 14.8 14 29.2 
Unknown 17 10.4 13 11.3 4 8.3 
aChi-square test. bTreatment regimens were divided into vincristine and actinomycin (VA)-containing and non-VA-containing. VAC/VAI(A),
vincristine, D-actinomycin, cyclophosphamide/iphosphamide, (doxorubicin); DIME, doxorubicine, iphosphamide, mesna, etoposide; EVI, etoposide,
vindesine/vincristine and iphosphamide. cClinical group was based on the extent of residual tumor after the initial surgical resection, according to
the clinical grouping system of the Intergroup Rhabdomyosarcoma Study Group. Percentages of treatment modalities (chemotherapy, radiotherapy,
surgery and clinical group) were calculated as the percentage of all patients treated with curative intention of treatment (N=163).
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Figure 2. Rhabdomyosarcoma survival. Kaplan-Meier overall survival (OS) curves for patients with rhabdomyosarcoma (RMS) by age group (A), patients
<16 years: N=118 patients, N at 5 years=51, patients ≥16 years: N=50 patients, N at 5 years=7; by histological subtype (B), embryonal RMS: N=102
patients, N at 5 years=41, botryoid RMS: N=15 patients, N at 5 years=8, and alveolar RMS: N=51 patients, N at 5 years=9; by age group for embryonal
RMS (C), patients <16 years: N=78 patients, N at 5 years=36, patients ≥16 years: N=24 patients, N at 5 years=5; by age group for alveolar RMS (D),
patients <16 years: N=26 patients, N at 5 years=7, patients ≥16 years: N=25 patients, N at 5 years=2; for non-metastatic embryonal RMS, non-metastatic
alveolar RMS and metastatic embryonal and alveolar RMS (E), non-metastatic embryonal RMS: N=90 patients, N at 5 years 40, non-metastatic alveolar
RMS: N=27 patients, N at 5 years=8, metastatic embryonal and alveolar RMS: N=35 patients, N at 5 years=2; and by age group for non-metastatic
embryonal (F), patients <16 years at diagnosis: N=72 patients, N at 5 years=36, patients ≥16 years at diagnosis: N=18 patients, N at 5 years=4.
lymph node involvement (p=0.023, HR=1.94) and the presence
of metastatic disease (p=0.009, HR=2.16) were multivariate
predictors of poor DSS. Increasing age (p<0.001, HR=1.031)
was the only significant multivariate prognostic factor of poor
RFS, along with a trend towards a negative prognostic effect
of alveolar subtype (p=0.057, HR=1.96) and metastatic disease
(p=0.094, HR=1.89). To further exclude the interaction
between the effect of age and histological subtype on outcome,
we analyzed embryonal and alveolar RMS separately.
Embryonal RMS: In embryonal RMS (Table V), increasing
age (p=0.001, HR=1.038), unfavorable primary site
(p=0.006, HR=4.21), and lymph node involvement
(p<0.001, HR=5.47) were significant multivariate predictors
of poor DSS, whereas a trend was seen for metastatic disease
(p=0.063, HR=2.45). Higher age (p<0.001, HR=1.043),
unfavorable primary site (p=0.033, HR=2.50), and lymph
node involvement (p=0.015, HR=3.47) were multivariate
predictors of poor RFS. 
To eliminate a possible effect of metastatic disease in older
patients as mentioned before, non-metastatic embryonal RMS
was analyzed separately (Table VI). Increasing age (p=0.001,
HR=1.045), unfavorable primary site (p=0.011, HR=4.00),
and lymph node involvement (p<0.001, HR=6.44) were
significant multivariate predictors of poor DSS, whereas
higher age (p<0.001, HR=1.043), and unfavorable primary
site (p=0.045, HR=2.52) were predictors of poor RFS.
Furthermore, we investigated the effect of treatment
modalities (chemotherapy, radiotherapy, surgery, and Clinical
Group I-IV) on DSS in non-metastatic embryonal RMS. In
univariate analysis, no administration of chemotherapy
(p=0.011, HR=5.19, 95% Confidence Interval (CI)=1.47-
18.63), no surgery for primary tumor and/or metastases
(p=0.004, HR=3.66, 95% CI=1.515-8.83), and Clinical
Group III versus I (p=0.013, HR=5.06, 95% CI=1.41-18.20)
predicted poor DSS. In a multivariate model including age,
lymph node involvement, primary tumor location, Clinical
ANTICANCER RESEARCH 32: 4485-4498 (2012)
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Table IV. Prognostic factors in Cox proportional hazards analysis for all patients.
Disease-specific survival Relapse-free survival
Patient Prognostic 
group factor Univariate Multivariate Univariate Multivariate
p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI 
All RMS Age <0.001 1.042 1.028-1.056 <0.001a 1.028 1.012-1.044 <0.001 1.039 1.023-1.054 <0.001b 1.031 1.013-1.048
Type <0.001 0.643 <0.001 0.162
Embryonal Reference Reference Reference Reference
Botryoid 0.778 0.860 0.302-2.453 0.715 0.818 0.280-2.394 0.955 1.031 0.358-2.963 0.753 1.19 0.402-3.527
Alveolar <0.001 3.626 2.206-5.960 0.578 1.283 0.675-2.441 <0.001 3.501 2.009-6.104 0.057 1.964 0.979-3.938
Local extension 0.01 3.993 1.382-11.192 NI 0.125 2.016 0.824-4.935 NI
Favorability <0.001 4.226 2.159-8.272 0.012 2.512 1.221-5.167 0.002 2.697 1.446-5.032 0.154 1.642 0.830-3.245
Lymph nodes <0.001 3.307 2.055-5.332 0.023 1.935 1.095-3.420 0.012 2.027 1.169-3.517 0.615 1.179 0.620-2.242
Metastases <0.001 4.434 2.680-7.336 0.009 2.161 1.209-3.863 <0.001 3.826 2.046-7.153 0.094 1.893 0.900-3.757
IRS stage <0.001 NI <0.001 NI
I Reference Reference
II 0.023 3.856 1.206-12.331 0.019 3.827 1.245-11.760
III 0.008 2.763 1.307-5.838 0.101 1.819 0.891-3.714
IV <0.001 8.378 4.000-17.547 <0.001 5.821 2.683-12.628
Size 0.443 1.309 0.658-2.607 NI 0.313 1.440 0.709-2.928 NI
NI, Not included; NS, not significant at p<0.05; HR, hazards ratio; CI, confidence interval. Embryonal rhabdomyosarcoma and IRS stage I was used
as a reference for calculating significance and HR of Cox proportional hazards analysis when applicable. aMultivariate analysis on disease-specific
survival (DSS) (N=167, 68 events), including age, histological type, site favorability (as defined by the IRSG), lymph node involvement, and the presence
of metastatic disease. Invasiveness and size were not included because of lack of availability on data on these items, leading to very small patient
numbers. A model with only age and type results in a significant effect of age (p<0.001, HR=1.034, 95% CI=1.018-1.050) and type (alveolar versus
embryonal, p<0.001, HR=2.811, 95% CI=1.683-4.696) on outcome (N=168). Addition of IRS stage instead of lymph node involvement, site and
metastatic disease, resulted in a significant effect of age (p<0.001, HR=1.036, 95%CI=1.020-1.054) and IRS stage III (p=0.033, HR=2.306,
95%CI=1.068-4.980) and IV (p<0.001, HR=4.801, 95% CI=2.073-11.120) versus 1 (N=156 patients). A trend towards an interaction between age and
histological subtype on DSS was found (p=0.098). bMultivariate analysis on relapse-free survival (RFS), including all patients with complete remission
at the end of treatment (N=130, 54 events). Prognostic factors of age, histological type, site favorability (as defined by the IRSG), lymph node
involvement, and the presence of metastatic disease were included. Invasiveness and tumor size were not included. A model with IRS stage instead of
lymph node involvement, site and metastatic disease (N=120, 49 events), resulted in a significant effect of age (p<0.001, HR=1.044, 95% CI=1.025-
1.064) and IRS group IV versus I (p=0.025, HR=2.840, 95% CI=1.138-7.091). There was no interaction (p=0.313) between the effect of age and
histological subtype on RFS.
Group, radiotherapy, chemotherapy and surgery (N=79),
higher age (p=0.005, HR=1.07, 95% CI=1.019-1.115),
lymph node involvement (p=0.003, HR=6.51, 95% CI=1.90-
22.25), Clinical group III versus I (p=0.021, HR=23.45, 95%
CI=1.61-342.34), and no radiotherapy (p=0.048, HR=3.68,
95% CI=1.01-13.37) were predictors of poor DSS. 
Alveolar RMS: In alveolar RMS (Table VII), there was a
trend for poorer DSS with increasing age (p=0.078,
HR=1.02), and metastatic disease (p=0.095 HR=1.82). A
nearly identical result was seen for RFS.
Discussion
In this multicenter retrospective clinical study, we
demonstrated in multivariate analysis that increasing age as a
continuous variable is a strong prognostic factor of a poor
therapeutic outcome in patients with embryonal and alveolar
RMS aged 0-73 years. Moreover, histological subtype and
clinical presentation at diagnosis (e.g. tumor location, lymph
node involvement and presence of metastatic disease) were
prognosticators of outcome in the whole cohort. 
Whereas prognostic factors in children with RMS have been
investigated extensively over the past decades (5-8), until
recently, data on prognostic factors in adult patients were
scarce, most likely due to the rarity of these tumors and the
dispersion of patients treated in adult oncology centers (11). 
Our study confirms previous findings in cohorts aged 0-75
years, with additional correction for treatment modalities. La
Quaglia et al. were the first who described both adults and
children with RMS and found age, TNM stage, and
histological subtype to be prognostic factors of survival (22).
Furthermore, a population-based study including 2,600
patients of all ages with RMS, was recently published (12),
indicating that age, histological subtype, primary site location,
stage, and local control with surgery and/or radiation were
significant predictors of survival. In contrast to that large
study, in this present study we attempted to add an analysis of
chemotherapy schedules that were administered, excluding
pleiomorphic RMS, which occurs exclusively in adults. 
Histological subtype is an established prognostic factor of
survival in RMS in children. This holds true with the present
findings for the whole cohort in univariate analysis.
Moreover, results of our multivariate model for the whole
cohort indicate that this disadvantage in outcome for alveolar
RMS might have a stronger relation to an unfavorable clinical
presentation (e.g. unfavorable primary site and the presence
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Table V. Prognostic factors in Cox proportional hazards analysis for patients with embryonal rhabdomyosarcoma (ERMS). 
Disease-specific survival Relapse-free survival
Patient Prognostic 
group factor Univariate Multivariate Univariate Multivariate
p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI 
Embryonal Age <0.001 1.043 1.022-1.064 0.001a 1.038 0.015-1.062 0.001 1.037 0.016-1.059 <0.001b 1.043 1.021-1.067
RMS Local extension 0.038 3.739 1.074-13.019 NI 0.187 2.003 0.714-5.621 NI
Location 0.002 4.682 1.779-12.321 0.006 4.214 1.513-11.736 0.033 2.500 1.078-5.798 0.033 2.656 1.080-6.537
Lymph nodes <0.001 4.411 2.091-9.302 <0.001 5.466 2.407-12.411 0.171 1.898 0.758-4.756 0.015 3.468 1.270-9.469
Metastases <0.001 5.721 2.364-13.846 0.063 2.450 0.951-6.312 0.178 2.656 0.623-11.329 0.411 1.872 0.420-8.339
IRS stage <0.001 NI 0.011 NI
I Reference Reference
II 0.027 6.379 1.233-32.986 0.002 8.688 2.274-33.198
III 0.022 3.433 1.192-9.887 0.173 1.939 0.748-5.029
IV <0.001 12.757 3.968-41.014 0.069 4.222 0.893-19.956
Gender 0.968 1.016 0.460-2.247 NI 0.872 1.071 0.462-2.483 NI
Size 0.239 1.848 0.665-5.135 NI 0.170 2.031 0.738-5.590 NI
NI, Not included; NS, not significant at p<0.05; HR, hazards ratio; CI, confidence interval. IRS stage I was used as a reference for calculating
significance and HR of Cox proportional hazards analysis when applicable. aMultivariate analysis on disease-specific survival (N=101, 27 events),
including age, site favorability (as defined by the IRSG), lymph node involvement, and the presence of metastatic disease. Invasiveness and size were
not included because of lack of availability on data on these items, leading to very small patient numbers. Addition of IRS stage instead of lymph node
involvement, site and metastatic disease, resulted in a significant effect of age (p<0.001, HR=1.055, 95%, CI=1.025-1.085) and IRS stage III (p=0.014,
HR=3.793, 95% CI=1.306-11.015) and IV (p<0.001, HR=9.257, 95% CI=2.886-29.893) versus 1 (N=95, 25 events). bMultivariate analysis on relapse-
free survival, including all patients with complete remission at the end of treatment (N=82, 24 events). Prognostic factors of age, site favorability (as
defined by the IRSG), lymph node involvement, and the presence of metastatic disease were included. Invasiveness and tumor size were not included.
A model with IRS stage instead of lymph node involvement, site and metastatic disease (N=77, 22 events), resulted in a significant effect of age
(p<0.001, HR=1.059, 95% CI=1.033-1.085) and IRS II versus 1 (p=0.004, HR=7.391, 95% CI=1.911-28.583) and a trend towards a significant effect
of IRS II (p=0.063, HR=2.544, 95% CI=0.949-6.815) and IRS IV (p=0.074, HR=4.172, 95%, CI=0.872-19.964) versus I respectively. 
of lymph node and distant metastases) than to alveolar
histology itself, as reported by Sultan et al. (12). In addition,
a trend for unfavorable primary location (i.e. parameningeal)
and lymph node involvement at a higher age in alveolar RMS
was found, which might explain the worse outcome in older
patients. However, it should be mentioned that the
documentation and assessment of lymph node involvement
was suboptimal during the early time-period. Nevertheless,
the reported effect of lymph node involvement on survival in
the current study is in line with a recent report, and supports
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Table VI. Prognostic factors in Cox proportional hazards analysis for patients with non-metastatic embryonal rhabdomyosarcoma (ERMS, M0).
Disease-specific survival Relapse-free survival
Patient Prognostic 
group factor Univariate Multivariate Univariate Multivariate
p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI 
Embryonal Age <0.001 1.045 1.021-1.070 <0.001a 1.045 1.019-1.070 <0.001 1.041 1.019-1.064 <0.001b 1.043 1.021-1.067
RMS, M0 Local extension 0.055 4.375 0.969-19.750 NI 0.112 2.482 0.809-7.617 NI
Favorability 0.017 3.416 1.241-9.404 0.011 3.966 1.379-11.409 0.067 2.252 0.944-5.371 0.045 2.515 1.022-6.191
Lymph nodes 0.001 4.321 1.786-10.452 <0.001 6.439 2.490-16.647 0.285 1.723 0.635-4.671 0.058 2.802 0.964-8.147
IRS stage 0.029 NI 0.006 NI
I Reference Reference
II 0.025 6.549 1.265-33.911 0.001 8.952 2.337-34.295
III 0.022 3.441 1.194-9.912 0.171 1.946 0.750-5.047
Size 0.184 2.156 0.695-6.688 NI 0.173 2.033 0.732-5.645 NI
NI, Not included; NS, not significant at p<0.05; HR, hazards ratio; CI, confidence interval. IRS stage I was used as a reference for calculating
significance and HR of Cox proportional hazards analysis when applicable. aMultivariate analysis on disease-specific survival (N=88, 20 events),
including age, site favorability (as defined by the IRSG), and lymph node involvement. Addition of IRS stage instead of lymph node involvement,
and site, resulted in a significant effect of age (p<0.001, HR=1.064, 95% CI=1.030-1.098) and IRS III versus I (p=0.013, HR=3.916, 95% CI=1.338-
11.462 (N=82, 18 events). bMultivariate analysis on relapse-free survival, including all patients with complete remission at the end of treatment
(N=78, 22 events). Prognostic factors of age, site favorability (as defined by the IRSG), and lymph node involvement were included. A model with
IRS stage instead of lymph node involvement, and site (N=73, 20 events), resulted in a significant effect of age (p<0.001, HR=1.065, 95% CI=1.037-
1.093), IRS II (p=0.003, HR=7.692, 95% CI=1.982-29.855) and a trend for IRS III (p=0.057, HR=2.621, 95% CI=0.974-7.055) versus I, respectively.
Table VII. Prognostic factors in Cox proportional hazards analysis for patients with alveolar rhabdomyosarcoma (ARMS). 
Disease-specific survival Relapse-free survival
Patient Prognostic 
group factor Univariate Multivariate Univariate Multivariate
p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI 
Alveolar Age 0.043 1.023 1.001-1.045 0.078a 1.02 0.998-1.043 0.077 1.024 0.997-1.052 0.091b 1.023 0.996-1.050
RMS Local extension 0.217 3.613 0.470-27.772 NI 0.467 2.159 0.271-17.188 NI
Location 0.094 2.455 0.858-7.029 0.258 1.918 0.621-5.928 0.467 1.448 0.510-4.343 0.961 1.031 0.303-3.510
Lymph nodes 0.154 1.625 0.834-3.165 0.840 1.078 0.520-2.235 0.286 1.526 0.702-3.317 0.821 1.117 0.449-2.780
Metastases 0.098 1.767 0.901-3.407 0.095 1.824 0.901-3.694 0.073 2.107 0.932-4.761 0.091 2.091 0.890-4.913
IRS stage 0.402 NI 0.318 NI
I Reference Reference
II 0.811 1.245 0.207-7.493 0.585 0.532 0.055-5.117
III 0.254 2.128 0.581-7.796 0.526 1.539 0.406-5.836
IV 0.131 2.607 0.752-9.031 0.179 2.455 0.663-9.082
Size 0.564 0.746 0.276-2.019 NI 0.580 0.734 0.245-2.197 NI
NI, Not included; NS, not significant at p<0.05; HR, hazards ratio; CI=confidence interval. IRS stage I was used as a reference for calculating
significance and HR of Cox proportional hazards analysis when applicable. aMultivariate analysis on disease-specific survival (N=50, 37 events),
including age, histological type, site favorability (as defined by the IRSG), and lymph node involvement. Addition of IRS stage instead of lymph node
involvement, and site, did not provide additional information (N=48). bMultivariate analysis on relapse-free survival, including all patients with complete
remission at the end of treatment (N=36, 27 events). Prognostic factors of age, site favorability (as defined by the IRSG), and lymph node involvement
were included. A model with IRS stage instead of lymph node involvement, and site (N=73, 20 events), did not give any additional information.
the view that lymph node involvement should be considered
as an important prognosticator, especially in alveolar RMS
(26). Regarding histological subtype, it should be taken into
account that refinement of the histological diagnosis of RMS
with molecular and genetic diagnostic techniques has been
discribed in other studies during the period of our present
research (7, 27). 
Metastatic disease is a strong adverse prognostic factor in
all patients with RMS, leading to poor survival not exceeding
30% (11, 12, 28, 29). In our cohort, 5-year overall survival of
patients with metastatic disease hardly exceeded 10%.
Importantly, the presence of metastatic disease correlated
with higher age at diagnosis, even in the restricted group of
embryonal RMS. Unfavorable clinical presentation with
increasing age was also reported by others (11, 20, 21).
Importantly, we found age to be a prognosticator of DSS in
non-metastatic embryonal RMS. Although age as a
prognostic factor in this particular subset of patients has been
previously reported (22), to our knowledge, the present study
is the first that has evaluated age as a continuous factor in
multivariate analysis including treatment modalities. 
Apart from tumor-specific factors, treatment-related
aspects play a role in the final outcome of RMS patients.
Pediatric patients (up to 21 years) are generally treated on
study protocols developed by, for example, the SIOP
(Europe) and COG (formerly IRSG, United States),
including systemic treatment for all patients. In adults, we
show that systemic treatment is administered, although less
frequently, and comprising other agents. Of note,
anthracyclines were applied more frequently as part of the
primary treatment for adult patients. The underlying reason
for this discrepancy in the treatment approach is not fully
clear. The lack of international protocols for the elder RMS
population and the rarity of the disease within the adult
oncologic population may play an important role (30).
Although we found that age remained of prognostic
significance after including treatment modalities in a
multivariate model, we were not able to correct for the
different regimens and the given dose intensities. Whether
these observed differences in chemotherapy schedules might
play a role should be further investigated. Importantly,
Ferrari et al. previously hypothesized that survival in adults
would be comparable to that of children, if they received the
appropriate treatment as prescribed in the current childhood
regimens (11).
Other suggested explanations for poor survival of adults
with RMS are differences in oncogenesis and biological
behavior. Advanced clinical presentation with increasing
age, as well as age per se being a prognostic factor in
uniformly treated children, support this idea (17, 26, 31, 32).
Despite investigations focusing on understanding
oncogenesis and biological behavior, limited data are
available with regard to age-related biological differences of
RMS. Younger onset of RMS is associated with several rare
syndromes that harbor specific genetic alterations, including
those of the germline p53 tumor-suppressor gene, HRAS
oncogene, and neurofibromin (NF1) gene, suggesting a
different genetic background for early RMS genesis within
these patients (33). Furthermore, the PAX7/FKHR
translocation t(1;13)(p36;q14) in alveolar RMS, is
associated with younger onset of disease, primaries of the
extremity, localized disease, and better outcome, whereas
the more common PAX3/FKHR translocation
t(2;13)(q35;q14) is associated with higher age at diagnosis
and represents a highly malignant phenotype with a
predilection for bone marrow involvement and worse
outcome (34, 35). However, although a recent study
confirmed the relation of PAX3/FKHR with a higher age and
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Table VIII. Treatment intention and follow-up.
Treatment intention N N N N
No curative treatment 6 Died due before start of treatment 3
Palliative treatment intention 2
Unknown 1
Curative treatment 163 Did not complete treatment 22 Died due to toxic side effects 9
Ended treatment due to severe side-effects 2
Progression during treatment 10 Distant failure 9
Local progression 1
Unknown 1
Completed treatment 141 Refractory disease 5
Complete remission 135 Local failure 21
Distant failure 30
Local + distant failure 7
NEDa 77
aNED=No evidence of disease. This table displays the number of patients included in the study and the treatment intention, as well as data on
completement of treatment and follow-up. 
metastatic potential, it did not confirm a higher rate of bone
marrow involvement and worse outcome for patients with
these tumor types (36). A higher expression of drug-efflux
pumps in adult RMS, thereby potentially contributing to
worse response to chemotherapy, was also proposed to
explain differences in terms of biological behavior (37).
Conclusion
In conclusion, age is a strong adverse prognostic factor of
survival in patients with embryonal and alveolar RMS.
Whether the dismal outcome is caused by a biological or
treatment effect remains to be elucidated. With the
introduction of more homogeneous treatment protocols for
both children and adults, the contribution of age-related
biological factors can be further explored. Given the
presumably lower tolerance of adults to high doses of
chemotherapy administered in childhood RMS (20), dose
schedules should be adapted. Based on the results of our
study and the recently published SEER data, collaboration
between pediatric and medical oncologists regarding patients
with RMS is urgently needed, and should ideally take place
at a global level, given the rarity of these tumors (30).
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